


(I).

In the compound of Formula I, the dashed line is absent or a bond. X is O or S. R^1 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl, optionally substituted with from 1 to 3 R^{1a} groups. Each R^{1a} is independently H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkyl-OR^{1b}, halogen, C_{1-6} haloalkyl, C_{1-6} haloaloxy, -OR^{1b}, -$NR^{1b}R^{1c}$, -$C(O)R^{1b}$, -$C(O)OR^{1b}$, -$OC(O)R^{1b}$, -$C(O)NR^{1b}R^{1c}$, -$NR^{1b}C(O)R^{1c}$, -SO_2R^{1b}, -$SO_2NR^{1b}R^{1c}$, cycloalkyl, heterocycloalkyl, aryl or heteroaryl. R^{1b} and R^{1c} are each H or C_{1-6} alkyl. R^2 is H, C_{1-6} alkyl, C_{1-6} alkyl-OR^{1b}, C_{1-6} alkyl-$NR^{1b}R^{1c}$ or C_{1-6} alkylene-heterocycloalkyl. R^3 is H or C_{1-6} alkyl. Ar is aryl, optionally substituted with 1-4 R^4 groups. Each R^4 is H, C_{1-6} alkyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl or C_{1-6} haloalkoxy. L^1 is a bond or C_{1-6} alkylene. Subscript n is an integer from 0 to 3. Also included are the salts and isomers of the compounds recited herein.

[0009a] In one aspect of the present disclosure, there is provided a use of a compound of Formula Id in the manufacture of a medicament for treating fatty liver disease, wherein the compound of Formula Id has the structure:



(Id)

wherein

each R^{1a} is independently H, C_{1-6} alkyl, halogen, or C_{1-6} haloalkyl;

R^2 is H, or C_{1-6} alkyl; and

each R^4 is H, C_{1-6} alkyl, halogen, or C_{1-6} haloalkyl;

and salts and isomers thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010] **Figure 1** shows the percentage of fat (lipid droplets) in Oil Red O stained livers from mice that received a high fat diet and Compound 1 (60mg/kg/day) relative to control mice that received a high fat diet and vehicle.


[0011] **Figure 2A and 2B** show Oil Red O staining of lipid droplets from livers from a mouse that received a high fat ("HF") diet and Compound 1 (Figure 2A) and a control mouse that received a high fat diet and vehicle (Figure 2B).

[0012] **Figure 3** shows the percentage of fat (lipid droplets) in Oil Red O stained livers from mice that received a high fat diet and either mifepristone or Compound 1 (60mg/kg/day) relative to control mice that received a high fat diet and vehicle. * $p<0.05$ "Compound 1" compared to "CTRL"

[0013] **Figure 4** shows triglyceride levels in livers of mice given a normal diet (the "CHOW" group), mice given a high fat diet for 3 weeks (the "HF-3wks" group), mice given a high fat diet for 6 weeks (the "HF-6wks" group), mice given a high fat diet and Compound 1 for 6 weeks (the "HF+118335-6wks"group), and mice given a high fat diet for 6 weeks with administration of Compound 1 only for the last 3 weeks (the "HF-118335 rev" group).

WHAT IS CLAIMED IS:

1. Use of a compound of Formula Id in the manufacture of a medicament for treating fatty liver disease, wherein the compound of Formula Id has the structure:



(Id)

wherein

each R^{1a} is independently H, C_{1-6} alkyl, halogen, or C_{1-6} haloalkyl;

R^2 is H, or C_{1-6} alkyl; and

each R^4 is H, C_{1-6} alkyl, halogen, or C_{1-6} haloalkyl;

or is a salt or isomer thereof.

2. The use of claim 1, wherein the fatty liver disease is alcohol related liver disease (ARLD) or nonalcoholic fatty liver disease (NAFLD).

3. The use of claim 2, wherein the alcohol related liver disease is alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH) or alcoholic cirrhosis.

4. The use of claim 2, wherein the nonalcoholic fatty liver disease is nonalcoholic steatohepatitis (NASH) or nonalcoholic cirrhosis.










5. The use of any one of claims 1 to 4, wherein each R^{1a} is C_{1-6} haloalkyl.









6. The use of any one of claims 1 to 5, wherein each R^{1a} is independently selected from the group consisting of H, Me, Et, F, Cl, or $-CF_3$.

7. The use of any one of claims 1 to 6, wherein each R^{1a} is $-CF_3$.

8. The use of any one of claims 1 to 7, wherein R^2 is H.


9. The use of any one of claims 1 to 8, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

, and


and salts thereof.

10. The use of any one of claims 1 to 9, wherein the compound has the formula:



or a salt thereof.

11. The use according to any one of claims 1 to 10, wherein said compound is a glucocorticoid receptor antagonist.

12. The use according to any one of claims 1 to 11, wherein said compound is a mineralocorticoid receptor antagonist.

13. The use according to any one of claims 1 to 12, wherein said compound inhibits glucocorticoid binding to the glucocorticoid receptor and is a mineralocorticoid receptor antagonist.

14. The use according to any one of claims 1 to 13, wherein said compound inhibits glucocorticoid binding to the glucocorticoid receptor with an inhibition constant (Ki) of between about 0.0001 nanomolar (nM) and about 1000 nM and is a mineralocorticoid receptor antagonist.